Komo

Genesis Therapeutics

Who are Genesis Therapeutics's decision-makers?

Genesis is founder-led by Evan Feinberg, with a technical and scientific leadership bench built for AI-native drug discovery.

CEO
Evan Feinberg
CTO/key exec
Sergey Edunov / Shifeng Pan
Founded
2019
Employees
100-250 estimated
HQ
Burlingame, CA
Notable
Stanford spinout
  • Evan Feinberg, Ph.D.CEO and co-founderFounded 2019Stanford-trained computational biophysicist behind Genesis and GEMS.
  • Sergey EdunovChief Technology OfficerExecutive teamFormer large-scale AI infrastructure leader; owns technical platform direction.
  • Will McCarthyChief Operating OfficerExecutive teamLeads operating execution as Genesis scales partnerships and pipeline work.
  • Shifeng Pan, Ph.D.Chief Scientific OfficerJoined leadership team in 2024Owns scientific strategy and drug discovery execution.

Who leads Genesis Therapeutics?

Evan Feinberg founded Genesis from Stanford AI and simulation research. Sergey Edunov, Will McCarthy, and Shifeng Pan cover the platform, operating, and scientific sides of the company.

Who actually makes buying decisions at Genesis Therapeutics?

Buying decisions likely depend on deal type. AI infrastructure and platform vendors should expect technical validation from CTO/AI platform teams, while pharma collaboration and lab vendors will route through discovery leadership, BD, and operations.

How is Genesis Therapeutics organized as it scales?

Genesis is organized around AI platform, drug discovery, wet-lab validation, partnering, and operations. That structure reflects a company moving from research platform to pipeline and partner delivery.

As of June 2026.Sources:Genesis about pageGenesis Molecular AI websitea16z investment list

Genesis Therapeutics — frequently asked questions

Read the full Genesis Therapeutics profile
More on Genesis Therapeutics
Who are Genesis Therapeutics's decision-makers — other companies
Agent CTA Background

Revenue work. On autopilot.

Start Free TrialBuilt for revenue teams who care about quality.